Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives $3.75 Average PT from Brokerages

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have been assigned an average rating of “Hold” from the seven ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $3.75.

Several equities research analysts have commented on the company. Wall Street Zen lowered Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings lowered shares of Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 16th.

Werewolf Therapeutics Trading Down 3.3%

NASDAQ:HOWL opened at $0.32 on Monday. Werewolf Therapeutics has a 12 month low of $0.31 and a 12 month high of $2.38. The stock has a 50 day moving average of $0.54 and a two-hundred day moving average of $0.67. The firm has a market cap of $15.70 million, a P/E ratio of -0.26 and a beta of 0.29.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04. On average, research analysts forecast that Werewolf Therapeutics will post -1.08 earnings per share for the current year.

Insider Transactions at Werewolf Therapeutics

In other news, Director Luke Evnin sold 305,741 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $0.70, for a total value of $214,018.70. Following the completion of the sale, the director directly owned 1,273,008 shares in the company, valued at $891,105.60. This represents a 19.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $0.35, for a total value of $145,918.85. Following the completion of the sale, the insider owned 303,719 shares of the company’s stock, valued at $106,301.65. This trade represents a 57.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,924,038 shares of company stock worth $2,025,440 over the last 90 days. 23.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of large investors have recently made changes to their positions in HOWL. AQR Capital Management LLC purchased a new stake in shares of Werewolf Therapeutics in the first quarter valued at approximately $79,000. Marshall Wace LLP purchased a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $113,000. Qube Research & Technologies Ltd purchased a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $48,000. Jane Street Group LLC purchased a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $409,000. Finally, Bank of America Corp DE grew its position in shares of Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after purchasing an additional 25,882 shares in the last quarter. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.